quizartinib + dabigatran etexilate

**Quizartinib + dabigatran etexilate** is a combination of two separate pharmaceutical agents: quizartinib, a potent and selective small molecule inhibitor of the fms-like tyrosine kinase 3 (FLT3) receptor, primarily used in the treatment of acute myeloid leukemia (AML) with FLT3 internal tandem duplication (ITD) mutations[3][6]; and dabigatran etexilate, a direct oral anticoagulant (DOAC) functioning as a prodrug of dabigatran, a reversible direct thrombin inhibitor, approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for treatment and prevention of venous thromboembolism. Quizartinib acts by inhibiting the aberrant FLT3 signaling after ITD mutation, which leads to increased proliferation and survival of leukemia cells[3][6]. Dabigatran etexilate is converted to dabigatran after oral absorption and inhibits thrombin, thereby preventing fibrin clot formation. This specific combination has been investigated for drug-drug interaction potential in clinical studies, notably examining whether quizartinib affects the pharmacokinetic profile of dabigatran etexilate in healthy adults[1][2].

Brand names

VanflytaPradaxa

Other names

quizartinib dihydrochloridedabigatran